Nanodropper, a pioneering US-based healthcare startup focused on improving access to vision-saving medications, has earned 2nd place in the prestigious K-Startup Grand Challenge 2024, securing its place among the most innovative startups worldwide. 

The competition, organized by the South Korean Ministry of SMEs and Start-ups, recognized Nanodropper for its transformative solution to medication waste and adherence barriers in eye care. 

At the heart of Nanodropper’s innovation is the Nanodropper Adaptor, a micro-volume delivery device designed to optimize the use of eyedrop medications. Compatible with over 90% of eyedrop bottles, this simple yet effective tool reduces droplet size to the appropriate volume. 

This not only lowers costs and extends the bottle life but can help improve patient adherence by minimizing side effects often caused by oversized drops. The result is a significant reduction in the overall financial burden for both patients and healthcare systems.

“We are truly honored to be recognized in the K-Startup Grand Challenge, and this victory is a testament to the impact Nanodropper can have in addressing critical challenges in eye care,” said Dr. Allisa Song, CEO of Nanodropper, a Korean-American entrepreneur. “Our goal is to make vision-saving medications more accessible and affordable, while improving patient outcomes and reducing waste. We’re excited to bring our solution to the Korean market and work with local ophthalmologists and the government to drive lasting change.”

The Nanodropper Adaptor has been validated through four clinical trials, demonstrating its effectiveness in improving patient outcomes, especially for those with glaucoma, a condition affecting millions worldwide. Professor Yoo Hyung-gon, a leading ophthalmologist based in Seoul, emphasized the importance of this innovation for Korean patients:

“I’m excited for Nanodropper’s potential to improve treatment efficacy by reducing the side effects of eye drops. In particular, I think it will be beneficial for patients who need to use chronic eyedrops, such as those with glaucoma and also patients who use multiple eye drops.”

Nanodropper’s win in the K-Startup Grand Challenge further solidifies the company’s position as a leader in health equity and innovation in eye care. The company is looking forward to expand its presence in South Korea to create a more sustainable, effective, and cost-efficient healthcare system.